# MACROGENICS, INC. (MGNX) · Edgar & Edgarette company card

> Macrogenics (MGNX) saw revenue fall 0.3% in FY2025 to $150 million, operating margin -48.7% against a -3.8% median for pharmaceutical preparations, equity 21.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1125345 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MGNX) · [JSON](https://www.pops4.com/boards/company/MGNX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $150M |
| Revenue growth, 1 year | -0.3% |
| Revenue growth per year | 17.9% |
| Operating margin | -48.7% (prior year -73.7%) |
| Net margin | -49.9% |
| Operating cash flow | −$81M |
| Capital spending | $2M |
| Free cash flow | −$83M |
| Cash | $57M |
| Long-term debt | — |
| Total assets | $257M |
| Total equity | $56M |
| Equity ÷ assets | 21.6% |
| Return on equity | -134.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -12.89 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -48.7% in FY2025; revenue is hard to predict: its 80% range is ±75%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $149.5M (FY2025). Experience: revenue down 0.3% on the year, up 17.9% a year over 4 years; operating margin -48.7%, up from -73.7%. Soundness: equity 21.6% of assets, return on equity -134.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $55.5M and $396.3M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $33.8M to $664.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -48.7% against a -3.8% median; growth -0.3% against 13.7%.

Range logged 2026-11-01, receipt 7832c9ba74a6b7f6, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000069/0001125345-26-000069-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000069/0001125345-26-000069-index.htm)
- 8-K · filed 2026-10-23 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000066/0001125345-26-000066-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000056/0001125345-26-000056-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/0001125345-26-000054-index.htm)
- 8-K · filed 2026-07-23 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000050/0001125345-26-000050-index.htm)
- 8-K · filed 2026-07-08 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000047/0001125345-26-000047-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001125345.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1125345

## Cite

POPS4, Edgar & Edgarette: MACROGENICS, INC. (MGNX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/MGNX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.